STOCK TITAN

Avalo Therapeutics (AVTX) SEC Filings, Aug 14-18, 2026

AVTX NASDAQ

Avalo Therapeutics, Inc. filings document clinical, financial, capital-structure, and governance disclosures for a biotechnology issuer developing IL-1β-based therapies. Recent 8-K reports cover abdakibart LOTUS trial materials in hidradenitis suppurativa, operating and financial results, investor presentation updates, and material agreements related to milestone obligations from the AlmataBio acquisition.

The company's proxy materials describe shareholder voting matters, board composition, executive compensation, equity awards, and governance practices. Avalo's filing record also includes disclosure categories tied to common stock and pre-funded warrant financing, Nasdaq inducement awards, risk and operating updates, and formal reporting of material events affecting its clinical-stage business.

Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) officer Christopher Ryan Sullivan has filed a notice under Rule 144 indicating an intent to sell up to 31,031 shares of common stock through Morgan Stanley Smith Barney. The shares relate to option exercises under a registered plan, including blocks of 25,124 and 5,907 shares for services rendered, with a proposed sale date of 08/18/2026. In the prior three months, Sullivan sold 3,749 shares for proceeds of $74,762.10.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.28%
Tags
other
-
Rhea-AI Summary

AVTX insider Mittie Doyle notified an intention to sell 5,037 shares of common stock on 08/17/2026, tied to an exercise of stock options, with a referenced value of $98,674.83. The notice also lists recent Rule 10b5-1 sales of AVTX common stock over the prior three months with specified share counts and dollar amounts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.20%
Tags
other
-
Rhea-AI Summary

Avalo Therapeutics, Inc. (AVTX) officer Christopher Ryan Sullivan submitted notice of a proposed sale of 70,709 common shares, with an aggregate market value of $1,385,189.31. The remarks state the shares were and will be received upon exercise of stock options over the next three months, with acquisition and payment dates corresponding to the exercise/sale dates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.20%
Tags
other
Rhea-AI Summary

A person associated with AVTX has filed a notice of intent to sell common stock. The planned sale covers 3,749 shares of AVTX common stock, with an indicated aggregate market value of 74,762.10, to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services on or after August 17, 2026 on the NASDAQ market.

The shares come from multiple sources, including 2,876 shares acquired via an exercise of options under a registered plan on August 17, 2026 and several smaller lots (such as 450 shares and 417 shares) purchased through an Employee Stock Purchase Plan between 2020 and 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.20%
Tags
other
-
Rhea-AI Summary

Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Avalo Therapeutics, Inc.

As of June 30, 2026, the reporting persons may be deemed to beneficially own 1,862,250 shares of Avalo Therapeutics common stock, representing 3.54% of the outstanding class. All reported shares are held by funds and separately managed accounts controlled by Nantahala, with the reporting persons having shared voting and dispositive power over these shares and no sole voting or dispositive power. Each of Harkey and Mack files as a control person in respect of shares beneficially owned by Nantahala, which is described as an investment adviser.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
ownership
-
Rhea-AI Summary

Caligan Partners LP and David Johnson report beneficial ownership of Avalo Therapeutics, Inc. common stock on an amended Schedule 13G. They report beneficial ownership of 3,163,866 shares of common stock, representing 5.9% of the class, based on 53,629,989 shares outstanding as of August 3, 2026.

The reporting persons have shared voting and dispositive power over all 3,163,866 shares and no sole voting or dispositive power. The shares are held by certain funds and accounts for which Caligan serves indirectly as investment manager, with David Johnson as Managing Partner of Caligan and Managing Member of its general partner.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
ownership
Rhea-AI Summary

RA Capital Management, L.P. and affiliated entities report beneficial ownership of 3,483,099 shares of Avalo Therapeutics, Inc. common stock as of June 30, 2026, representing 6.3% of the class. The holding consists of 1,000,000 common shares directly owned by RA Capital Healthcare Fund, L.P. and Series C preferred stock convertible into 2,483,099 common shares.

The ownership percentage is calculated based on 52,900,692 common shares outstanding plus the 2,483,099 shares issuable upon conversion of the preferred shares. Voting and dispositive power over the Fund’s holdings has been delegated to RA Capital, and the Fund disclaims beneficial ownership for Section 13(d) purposes. RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners under Section 13(d) but each disclaims beneficial ownership except for determining reporting obligations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
ownership
-
Rhea-AI Summary

Avalo Therapeutics, Inc. has a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert reporting aggregated holdings in Avalo’s common stock. As of June 30, 2026, these reporting persons collectively beneficially owned 2,801,545 shares of common stock, including shares issuable upon conversion of preferred stock, representing approximately 5.3% of the outstanding common stock.

The group holds 726 shares of Series C Non-Voting Convertible Preferred Stock, initially convertible into an aggregate of 726,000 common shares, subject to a 9.99% Beneficial Ownership Limitation, which did not restrict conversion at that time. The ownership percentages are based on 52,565,572 common shares outstanding as of May 8, 2026, plus the relevant convertible shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
ownership
-
Rhea-AI Summary

T. Rowe Price Investment Management, Inc. filed an amended ownership report for Avalo Therapeutics Inc. common stock. The firm reports beneficial ownership of 3,670 shares, representing 0.0% of the class, all with sole voting and dispositive power. It states that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
ownership
Rhea-AI Summary

Avalo Therapeutics, Inc. received an amended Schedule 13G filing indicating that Avoro Capital Advisors LLC and Behzad Aghazadeh collectively report beneficial ownership of 2,333,333 shares of Avalo common stock. This represents 4.44% of the outstanding common stock, based on 52,565,572 shares outstanding as of May 8, 2026. The reporting persons each have sole voting and sole dispositive power over these shares and no shared voting or shared dispositive power. The stake is held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and the filers state that the filing should not be construed as an admission of beneficial ownership for all purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
ownership

FAQ

How many Avalo Therapeutics (AVTX) SEC filings are available on StockTitan?

StockTitan tracks 184 SEC filings for Avalo Therapeutics (AVTX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Avalo Therapeutics (AVTX)?

The most recent SEC filing for Avalo Therapeutics (AVTX) was filed on November 16, 2026.